Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Chemomab Therapeutics Ltd. Sponsored ADR (CMMB : NSDQ)

• Company Description    Chemomab Ltd. is a clinical-stage biotech company. It focuses on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need. The company's product pipeline includes CM-101. Chemomab Ltd., formerly known as Anchiano Therapeutics Ltd., is based in TEL-AVIV, Israel. Number of Employees: 10

• Price / Volume Information    Yesterday's Closing Price: $2.02 Daily Weekly Monthly 20 Day Moving Average: 45,881 shares Shares Outstanding: 7.19 (millions) Market Capitalization: $14.53 (millions) Beta: 0.51 52 Week High: $5.77 52 Week Low: $1.35 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 24.69% 18.60% 12 Week 30.32% 20.48% Year To Date 22.42% 1.41%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 10 HABARZEL STREET BUILDING C 10TH FLOOR - TEL AVIV,L3 6158101 ISR ph: 972-77-331-0156 fax: - ir@chemomab.com http://www.chemomab.com

• General Corporate Information    Officers Adi Mor - Chief Executive Officer; Chief Scientific Officer Nissim Darvish - Chairman Sigal Fattal - Chief Financial Officer Alan Moses - Director Claude Nicaise - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 16385C203 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/13/26 Share - Related Items Shares Outstanding: 7.19 Most Recent Split Date: 8.00 (0.25:1) Beta: 0.51 Market Capitalization: $14.53 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.00 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.40 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.36 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 60.71% vs. Previous Quarter: 8.33% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -89.03 12/31/25 - -103.85 09/30/25 - -110.78 ROA 03/31/26 - -79.68 12/31/25 - -90.44 09/30/25 - -93.27 Current Ratio 03/31/26 - 10.31 12/31/25 - 9.08 09/30/25 - 10.49 Quick Ratio 03/31/26 - 10.31 12/31/25 - 9.08 09/30/25 - 10.49 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 1.49 12/31/25 - 2.00 09/30/25 - 2.17 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©